Why do millions of hearts pump normally yet still leave people breathless? In heart failure with preserved ejection fraction (HFpEF, said “heff-peff”), the heart squeezes fine but is too stiff to relax and refill. It affects an estimated 20 million-plus people worldwide and is hard to spot and hard to treat.
A new study from King’s College London found a hidden relaxation switch inside heart muscle, an enzyme called PKGIα with one tiny chemical handle (cysteine 42). Urolithin A, a molecule gut bacteria make from pomegranates, walnuts and berries, grabbed that handle and loosened stiff hearts in mice, improving filling, scarring and running distance. In mice bred without the handle, it did nothing. Lab-grown human heart tissue also relaxed faster.
What it is not: a treatment. This was male mice for one week plus lab tissue, using purified urolithin A at doses above anything food provides. We translate the mouse dose into human terms and walk through what would still need to be proven in people.
⏱️ Video Chapters
00:00 – Introduction: Pomegranates & Heart Failure (HFpEF)
00:34 – What is HFpEF? The Stiff Heart Challenge
01:15 – Gut Microbes, Urolithin A & The Relaxation Switch
02:03 – Why This Matters: Prevalence & Symptoms
03:05 – Study Overview: Unpacking the Research & Challenges in Treatment
04:01 – The Science: PKG1α, Cysteine Activation & Heart Function Results
05:20 – Infographic Breakdown: Fibrosis, Heart Rate & Muscle Cell Size
05:50 – Real-World Translation: What This Could Mean for Everyday Life
07:14 – Safety Profile, Oral Dosing & Body Surface Area Conversion
08:48 – Comparison to Muscle Dosing & Supplement Safety Margins
09:27 – Study Protocol, Diet Models & Limitations
10:13 – Navigating Research Quality: Study Selection & Scientific Rigor
11:30 – Accessing Full Infographics & Concluding Thoughts
🔍 Key Highlights Covered:
The Stiff Heart Problem: About 43% of heart failure cases involve preserved ejection fraction (HFpEF), where the heart pumps normally but struggles to relax and fill with blood.
The Mechanism: Urolithin A targets a specific cysteine residue on PKG1α, triggering the pathway that allows cardiac muscle relaxation and reduced fibrosis.
Translational Potential: Comparing animal dosing to human equivalents and what human clinical trials will need to confirm.
📌 Resources & References: Find full infographics and detailed study breakdown notes at clinicalnews.org.
📄 Study:
Su J, Zhao Y, Coleman P, et al., Burgoyne JR. Targeting PKGIα Cys42 attenuates cardiac dysfunction in heart failure with preserved ejection fraction. Science Advances 12, eaec8088 (2026). https://doi.org/10.1126/sciadv.aec8088
⚠️ Educational purposes only. Not medical advice. If you have heart failure, talk with your cardiologist before adding any supplement. Non-monetized, no sponsorships.
Narrator: Ralph Turchiano | Analysis: Claude (Anthropic)
ClinicalNews.org | VHFILM
#UrolithinA #HeartFailure #HFpEF #HeartHealth #ScienceNews